Drugs and patents in ATC class M04A - ANTIGOUT PREPARATIONS

Last updated: July 27, 2026

ATC M04A (antigout preparations) is dominated by small-molecule urate-lowering drugs (ULTs) and symptom-control anti-inflammatories. Patent risk is concentrated in: (1) branded ULT formulations and dosing regimens, (2) kidney-sparing or “improved” ULT use cases, and (3) controlled-release or combination products. Across M04A, generic entry is most constrained where the brand estate couples active ingredient composition-of-matter with long-lived formulation, method-of treatment, or process patents, and where FDA Orange Book continuity supports strong patent “coverage” at the NDA/NJ-like listing level.

What drugs are in ATC M04A antigout preparations, and how is the patent estate structured?

ATC M04A covers antigout therapies, including xanthine oxidase inhibitors (XOIs), uricosurics, uricase products, and anti-inflammatory agents used for acute gout flares and prophylaxis around ULT initiation. Patent landscapes differ sharply by drug class.

Which active ingredients drive M04A revenue and patent focus?

Common M04A drug categories by mechanism:

Xanthine oxidase inhibitors (XOIs): allopurinol, febuxostat
Uricosurics: probenecid (where marketed), lesinurad (where present by region and brand availability)
Urate-lowering biologic: pegloticase (uricase conjugate) in markets where authorized
Acute flare anti-inflammatories and prophylaxis: colchicine, corticosteroids, NSAID products (often multiple generics)

Patent concentration in practice:

Largest branded/IP exposure: XOIs (especially febuxostat where brands historically had complex estates) and pegloticase (biologic exclusivity + formulation/manufacturing + device-like aspects for biologics).
High generic penetration: allopurinol and colchicine in most mature markets, with fewer remaining “commercially binding” patents.
Combination products and specialty formulations: where present, drive the “last-mile” patent coverage (dose titration instructions, prophylaxis regimens, or controlled-release formats).

How do patents typically break down within M04A?

A typical M04A patent estate splits into:

Composition of matter for the active ingredient (strong, but usually early and expiring).
Formulation patents (crystalline forms, polymorphs, particle size, excipients, sustained-release matrices, lyophilized products for biologics, stabilizers).
Method-of-treatment patents (treat-to-target dosing, flare prophylaxis schedules, renal impairment subgroups, combination therapy rules).
Manufacturing/process patents (especially for biologics and pegylated products).
Device or packaging-adjacent protections in rare cases (more common outside M04A, but packaging IP can affect enforceability).

How do exclusivity timelines work for M04A drugs in the U.S., and when does protection end?

For U.S. exclusivity, there are two parallel “clocks”: regulatory exclusivity (exclusivity periods tied to exclusivity grants) and patent life (Orange Book-listed patents that block generic substitution via Paragraph IV/Hatch-Waxman).

What is the regulatory exclusivity framework that affects M04A?

New Chemical Entity (NCE) exclusivity: 5 years for certain NDAs
Orphan drug exclusivity: 7 years (if designated and applicable)
Pediatric exclusivity: 6 months add-on (if studies conducted)
505(b)(1)/(b)(2) exclusivity and Hatch-Waxman carve-outs: can alter timing for follow-on products
Biologics/351(a) exclusivity (for uricase products): biologics pathway uses biologic-specific exclusivity constructs

When does “effective launch freedom” typically arrive for M04A generics?

Effective freedom generally requires:

Patent expiration (or non-infringement/non-validity outcomes) for Orange Book-listed patents covering the drug/strength/form.
Resolution of Paragraph IV litigation if a generic challenges listed patents.
Any residual regulatory exclusivity on the reference listed drug (RLD), especially for biologics and orphan-designated products.

In practice, many M04A molecules reached U.S. generic maturity for core actives (e.g., allopurinol, colchicine). The remaining constraints often relate to:

form-specific patents (e.g., a particular controlled-release or a particular strength)
method-of-treatment coverage that can still be asserted, depending on how claims are drafted and how the generic label is carved
biologic exclusivity + process/formulation patent stacks for uricase products

What patents protect febuxostat and how strong is the patent estate for xanthine oxidase inhibitors?

Febuxostat is historically the most IP-sensitive XOI in many markets due to brand-specific patents. The estate usually includes:

composition-of-matter
crystalline form/polymorph variants
formulation and stability improvements
dosing regimens and patient selection

How many patent families usually cover febuxostat, and which claim types matter for generics?

For Hatch-Waxman generic substitution risk, the most binding claims are those that are:

Orange Book-listed at the NDA level and
drafted as composition-of-matter or formulation for the specific dosage form/strength.

Method-of-treatment claims can still drive litigation and label design constraints, but generic substitution (therapeutic equivalence) depends on the Orange Book listing coverage rather than whether method claims exist in the abstract.

Featured snippet answer: which patent types block febuxostat generics longest?

Orange Book-listed formulation/polymorph patents plus any pediatric exclusivity add-ons and late-expiring method-of-treatment claims that map to label language.

What patents protect allopurinol and why is generic risk usually lower?

Allopurinol’s patent period is largely mature. Where IP persists, it is typically:

formulation-specific improvements,
manufacturing/process patents with less direct Orange Book blocking power, or
residual method-of-treatment coverage that can be managed via label carve-outs.

How do label carve-outs typically affect allopurinol method patents?

Generic labeling often avoids direct overlap with method claims by:
- not claiming specific titration schedules
- not limiting to narrow renal subpopulations where method patents are strongest
- using label language that fits FDA-approved generic labeling rather than brand-specific titration protocols

For most mature markets, enforcement intensity on method patents tends to be lower once generics dominate.

Which patents protect probenecid, and what generic entry risks remain?

Uricosuric probenecid is frequently genericized. The remaining risk tends to be:

brand-specific formulations (rare)
method-of-treatment claims that were preserved for specific clinical niches
legacy process patents tied to older manufacturing routes

Commercial implication for M04A

If probenecid is available primarily as generics, market leverage shifts to:

pricing competitiveness,
supply reliability, and
payer and formulary positioning rather than patent enforcement.

What patents protect pegloticase (uricase biologic), and how does exclusivity extend beyond small molecules?

Pegloticase is a biologic and carries a different protection stack:

biologic exclusivity (regulatory)
biologic manufacturing/process IP
formulation stability and conjugate-specific IP
delivery and administration-related components if claimed

How strong is the patent estate for pegloticase versus XOIs?

Generally stronger on duration and claim diversity because:

manufacturing and formulation patents often remain unexpired longer than composition-of-matter in biologics
process patents can be asserted even when active ingredient claims are expired
exclusivity timing can extend effective barriers against follow-on products

Biosimilar pathway relevance

A biosimilar (or “follow-on biologic” depending on regulatory framework) must navigate:

clinical comparability and
patent assertions that may cover manufacturing and formulation rather than only the active ingredient sequence.

What formulations are protected across M04A: tablets, capsules, injectables, and prophylaxis regimens?

Formulation patents matter most where they are Orange Book-listed and directly tied to marketed dosage forms.

Table: formulation and claim types that typically show up in M04A patent estates

M04A sub-class	Dosage form	Patent claim types most often asserted
XOIs (allopurinol/febuxostat)	tablets/oral solid	polymorph/crystal form, excipient systems, stability, process for API particle size
Uricosurics (probenecid/lesinurad where present)	oral solids	formulation stability, dosing regimen patents tied to treat-to-target and monitoring
Uricase biologics (pegloticase)	IV injectable	lyophilized formulation stability, conjugate-specific attributes, manufacturing/process steps
Flare/prophylaxis agents (colchicine/anti-inflammatories)	oral and injectable	fewer blockbuster formulation patents due to generic maturity; may include specific strength or delivery platform

What method-of-use patents cover gout treatment schedules, flare prophylaxis, and treat-to-target strategies?

Method-of-use claims are common in ULT. The strongest ones typically cover:

flare prophylaxis when initiating ULT
treat-to-target serum urate thresholds
dose titration schedules
renal impairment dosing paradigms

How do generic labels manage method-of-use patent exposure?

Generic sponsors typically design labels to:

avoid language that reads on method claims
remove instruction phrases that are specifically recited in claim limitations
comply with FDA-approved standard language for ULT initiation without tracking brand-specific titration protocols where those are patented.

What Paragraph IV challenges are filed for M04A drugs, and which targets trigger settlements?

In Hatch-Waxman, Paragraph IV filings are the practical entry event for generics. For M04A, the key is whether patents are:

Orange Book-listed for the relevant RLD and strength, and
drafted in a way that supports non-infringement defenses (common for formulation/process) or validity defenses.

Table: settlement patterns that recur in M04A

Trigger	Likely asserted patent types	Typical outcome pattern
Generic challenges ULT formulation patents	polymorph/formulation, API particle size, stability	partial carve-outs, design-around, or license if too costly to litigate
Generic challenges method-of-use patents	treat-to-target, prophylaxis schedule	label carve-out settlements, delayed launch for specific label items
Biologic follow-on challenge	process/manufacturing and formulation	longer timelines due to complexity and higher litigation cost

What is the Orange Book status of M04A drugs, and how do listed patents map to generic substitution?

Orange Book coverage determines whether generics can substitute under FDA rules while carving out patent-protected indications, strengths, or formulations.

Featured snippet answer: what controls Orange Book blocking power in M04A?

The Orange Book-listed patents that are tied to the drug’s active ingredient, dosage form, and strength. If those are expired or found not infringed, generic substitution accelerates.

How do manufacturing and IP barriers affect scale-up for M04A generics?

Even when patent barriers fall, manufacturing competence affects speed-to-market. IP barriers include:

API synthesis process know-how
polymorph control
stability and shelf-life data packages
sterile manufacturing controls for injectables (for biologics or branded injectables where protected)

Table: post-patent bottlenecks by drug type

Drug type	Manufacturing/IP bottleneck
Oral small molecules	polymorph consistency, stability, bioequivalence bridging
Injectable small molecules	sterile fill-finish process and stability at shelf conditions
Biologic uricase	cell line/process controls, conjugate quality attributes, comparability data and validation

Which companies compete in M04A across ULT and flare management, and where do patent risks concentrate?

The competitive field splits by:

mature generic markets (colchicine, allopurinol)
branded ULT and biologics where late patents and exclusivity extend barriers (febuxostat and pegloticase in markets where brands are still active)

Commercial implication

Where branded supply retains share, patent risk concentrates on:

line extensions (strength changes, formulation upgrades)
indication expansions or revised dosing regimens
any product relaunches that introduce new patents tied to the revised label.

How does M04A patent risk compare between gout ULTs and acute gout flare therapies?

ULT IP tends to create longer-lived enforcement because:

ULTs have chronic use and treat-to-target method claims
value capture is concentrated in a small number of ULT SKUs

Acute flare therapies often face faster generic saturation:

colchicine and NSAIDs generally enter as generics earlier
remaining IP is often formulation-specific rather than broad method coverage.

Table: risk ranking by M04A segment

Segment	Typical patent “time to expiry”	Generic penetration pace	Main remaining risk
ULT XOIs	medium to long	slower	formulation + method patents
Uricase biologics	long	slowest	biologic exclusivity + process/formulation
Flare therapies (colchicine/NSAIDs)	short to medium	fast	residual formulation/strength patents

What generic entry scenarios exist for M04A, and what launch dates are likely in practice?

Generic entry scenarios depend on:

whether the generic can achieve skinny label carve-outs that avoid method-of-use claims
whether it can develop a non-infringing polymorph or formulation
whether it faces biologic-specific complexity.

Table: generic entry route and key gating factors

Route	Typical approach	Main gating factor
Full generic (no carve-out)	bioequivalence + identical formulation	Orange Book-listed composition/formulation patents
Skinny label	omit patented indication or language	method-of-use claim alignment with label
Formulation design-around	new polymorph/excipient system	stability and equivalence + infringement of formulation patents
Follow-on biologic	comparability and clinical package	patent stack for manufacturing/formulation + biologic exclusivity

Key Takeaways

M04A’s patent landscape is dominated by ULT (XOIs) and pegloticase (uricase biologic), while acute flare therapies generally face faster generic saturation.
Patent enforcement that most affects generic entry is usually concentrated in Orange Book-listed formulation/polymorph patents and method-of-use claims tied to label language.
In the U.S., effective exclusivity ends when Orange Book-listed patents are expired or invalidated/non-infringed, after which label design and manufacturing competence determine launch timing.
For biologics in M04A, protection extends beyond composition-of-matter into manufacturing and formulation patents plus biologic exclusivity constructs, creating slower follow-on adoption.

FAQs

Which M04A drug classes have the highest likelihood of late-expiring formulation patents blocking generics?
How do skinny-label strategies work for gout method-of-use claims tied to treat-to-target dosing?
What patent claim types in pegloticase most commonly drive follow-on biologic litigation?
When do Orange Book patent listings expire for ULT strengths, and how does that affect generic substitution?
What manufacturing attributes (polymorph, particle size, sterile fill-finish) most affect non-infringing M04A formulation design?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
U.S. Food and Drug Administration. Hatch-Waxman Act and Drug Competition and Patent Term Restoration Act overview materials. FDA.
U.S. Food and Drug Administration. Exclusivity determinations and related regulatory exclusivity frameworks (NCE, orphan, pediatric). FDA.

Drugs in ATC Class M04A

Subclasses in ATC: M04A - ANTIGOUT PREPARATIONS

ATC Class M04A Antigout Preparations: Market Dynamics and Patent Landscape (Generics, Biosimilars, and Exclusivity Timelines)